3,661.00
+3.80%
Close of 9 Nov 2026, in DKK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genmab A/S
Its shares trade on Nasdaq Copenhagen under the ticker GMAB.CO. It has been listed since 1 October 2000. In the fiscal year to 31 December 2025, it reported revenue of $592.6m and net income of $153.4m. At that date it held total assets of $1.97bn and shareholders' equity of $895.7m.
Genmab A/S operates as an international biotechnology company. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Oct 2000
- Employees
- 579
- Website
- genmab.com ↗
Leadership
Pay as last reported
- Ms. Deirdre ConnellyIndependent Chairman of the Board, since 2017DKK 3.3m
- Dr. Jan Van De WinkelPresident, Chief Executive OfficerDKK 54.8m
- Ms. Pernille ErenbjergIndependent Deputy Chairman of the BoardDKK 2.6m
- Mr. Anthony PaganoChief Financial Officer, Executive Vice President, since 2020DKK 24.0m
- Mr. Christopher CozicExecutive Vice President, Chief People OfficerDKK 16.6m
- Mr. Rayne WallerExecutive Vice President, Chief Technical Operations OfficerDKK 7.3m
- Mr. Greg MuellerExecutive Vice President, General Counsel, Chief Legal Officer
- Dr. Tahamtan AhmadiExecutive Vice President, Chief Medical Officer, Head of Experimental Medicines, since 2021DKK 25.8m
- Mr. Brad BaileyExecutive Vice President, Chief Commercial OfficerDKK 11.1m
- Dr. Judith KlimovskyExecutive Vice President, Chief Development OfficerDKK 27.9m
- Ms. Martine Van VugtExecutive Vice President, Chief Strategy Officer, since 2023DKK 11.0m
- Mr. Michael KavanaghDirector - Employee Elected
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 95
- Environment
- 99
- Social
- 99
- Governance
- 86
- Direct emissions (scope 1)
- 534 t
- Energy emissions (scope 2)
- 2,705 t
- Value chain emissions (scope 3)
- 187,976 t
- Women in the workforce
- 57%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genmab A/S has a strong portfolio of innovative and differentiated biopharmaceutical products.
- The company has a robust research and development pipeline with potential for future growth and revenue generation.
- Genmab A/S has established strategic partnerships with leading pharmaceutical companies, enhancing its market presence and expanding commercial opportunities.
Weaknesses
- The company's dependency on a limited number of products makes it susceptible to fluctuations in the market and competitive pressures.
- Genmab A/S may face challenges in terms of regulatory approvals, as the biopharmaceutical industry is highly regulated.
- The high costs associated with research and development activities may strain the company's financial resources.
Opportunities
- The growing demand for innovative biopharmaceutical products presents significant growth opportunities for Genmab A/S.
- Strategic partnerships and collaborations can help the company expand its product portfolio and explore new markets.
- Advancements in technology and scientific discoveries provide potential for the development of breakthrough therapies.
Threats
- Intense competition within the biopharmaceutical industry may adversely affect Genmab A/S' market share and profitability.
- Delayed or unsuccessful clinical trials can impact the company's ability to bring products to market.
- Changes in healthcare policies and regulations can pose challenges to pricing and reimbursement of Genmab A/S' products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.